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Abstract Vaccination is considered to be one of the most effective
tools to decrease morbidity as well as mortality caused by
inﬂuenza viruses.
For the prevention of seasonal inﬂuenza, Fluarix  and FluLaval 
have been marketed since 1987 and 1992, respectively. Both
vaccines have consistently been shown to meet or exceed the
regulatory criteria for immunogenicity against the three strains
H1N1, H3N2 and B, have a good safety proﬁle, and are
recommended for vaccinating children and adults of all ages.
For the prevention of pandemic inﬂuenza, GlaxoSmithKline
(GSK) has obtained licensure of a pre-pandemic vaccine,
Prepandrix . This split-virus H5N1 adjuvanted with AS03, a
proprietary oil-in-water emulsion-based adjuvant system, has
demonstrated broad immunity against drifted H5N1 strains and
has been shown to be effective in preventing mortality and viral
shedding in animal studies.
The inﬂuenza vaccine portfolio of GSK addresses speciﬁc medical
needs related to seasonal or pandemic inﬂuenza viruses, which
remain an important public health threat worldwide.
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Introduction
Inﬂuenza is an acute, respiratory viral infection that is
usually self-limited in healthy adults and lasts about a week.
Inﬂuenza viruses circulate every winter in temperate regions
and throughout the year in tropical regions. The causative
agents are inﬂuenza A and inﬂuenza B viruses. The main
immunogenic factors are the virus surface glycoproteins
hemagglutinin (HA) and neuraminidase (NA). There are
several antigenic forms of HA and NA for inﬂuenza A
which is classiﬁed into different subtypes based on various
combinations of these antigens.
1–3 Only a limited number
of these inﬂuenza A subtypes are known to have been
associated with human disease and the ones currently in
circulation in the human population are H1N1 and H3N2.
4
Other inﬂuenza A subtypes such as H5N1, H7N7 and
H9N2 may sporadically cause human disease but have not
been transmitted widely so far through direct human to
human transmission. The inﬂuenza B virus belongs to two
evolutionary lineages that are distinct at the genetic and
antigenic levels and which are represented by B⁄Yamagata⁄
16⁄88-like and B⁄Victoria⁄2⁄87-like viruses that have
co-circulated in the population since the mid-1980s.
4–7
The HA and NA proteins of both inﬂuenza A and inﬂu-
enza B viruses are subject to continuous alteration in a
process of point mutations known as antigenic or genetic
drift with a consequence possible escape of the host
immune system by the viruses.
1,4,8,9 Antigenic drift is
responsible for the yearly seasonal, otherwise known as
inter-pandemic or epidemic inﬂuenza. Seasonal inﬂuenza is
usually a mild disease in the healthy adult population.
However, it causes signiﬁcant morbidity and mortality in
certain at-risk groups, i.e. elderly people aged 65 years and
above, young children and people with certain underlying
medical conditions.
10
Sometimes, a more profound antigenic change can occur,
and this antigenic shift can trigger the appearance of novel
highly transmissible viruses bearing surface antigens previ-
ously unknown to most of the human population’s immune
system. The combination of these factors has potentially
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pandemics, in which a large proportion of the worldwide
population is affected. Three major pandemics took place
during the 20th century: the ‘Spanish ﬂu’ in 1918–1919,
responsible for 20 to 50 million deaths worldwide, the ‘Asian
ﬂu’ in 1957 and the ‘Hong Kong ﬂu’ in 1968. These three
pandemics were caused either by reassortment of avian
viruses with the circulating human virus (‘Asian’ and ‘Hong
Kong’ ﬂu) or by a direct mutation of an avian virus
(‘Spanish’ ﬂu). More recently, in 1997, H5N1, a new subtype
of inﬂuenza appeared in South-East Asia and was trans-
mitted from birds to humans. This new form of the virus
has infected 385 individuals as of June 2008 (World Health
Organization [WHO] conﬁrmed cases),
11 resulting in 243
deaths (60% overall mortality rate), and has caused world-
wide concern about the possibility of the occurrence of a
new pandemic. Although H5N1 is the subtype considered
most likely to cause such a pandemic, other subtypes such as
H9N2, H2N2 or H7N7 are also possible candidates.
GSK inﬂuenza vaccine portfolio
Seasonal inﬂuenza
As recommended by the WHO, seasonal inﬂuenza vaccines
are trivalent, containing two inﬂuenza A strains (H1N1
and H3N2) and one inﬂuenza B strain.
1 However, to
ensure efﬁcacy against new drift viruses, the vaccine strains
must be updated on an annual basis for both the Northern
and Southern hemisphere. To support the ﬁnal strain selec-
tion, the WHO coordinates a global inﬂuenza surveillance
network to identify circulating viral strains.
12 Based on epi-
demiology and phylogenetic analysis of HA and NA
sequences of those human isolates, the WHO recommends
three strains that are anticipated to become dominant dur-
ing the next inﬂuenza season.
12 Although in most years the
recommendations accurately predict a close antigenic
match between the vaccine and circulating strains, some-
times a predominant circulating strain turns out to be anti-
genically different from the corresponding vaccine strain.
This can have a signiﬁcant negative impact on vaccine
efﬁcacy.
8,9,13,14
For the prevention of seasonal inﬂuenza, most govern-
ments in Western countries now recommend vaccination
to persons most at risk of developing complications, i.e.
elderly people aged 65 years and above and people with
speciﬁc underlying medical conditions. The United States
(US) and Canada have recently introduced new recommen-
dations to vaccinate all children aged 6 months to 18 years
and 6–59 months, respectively, not only to decrease mor-
bidity in the younger age group but also to decrease the
transmission of inﬂuenza in the community through herd
immunity. Finland has been the ﬁrst country in the Euro-
pean Union (EU) recommending the vaccination of all
children aged 6–35 months, regardless of health status, but
the introduction of similar measures is being considered in
Europe and in several other countries in Asia and
south⁄central America.
FluLaval 
FluLaval  is a trivalent inactivated split-virus inﬂuenza
virus vaccine, containing 15 lg HA from each of the three
recommended strains (H1N1, H3N2 and B). This vaccine
is manufactured in Quebec, Canada, where it has been
marketed since 1992 under the trade name Fluviral  and
is indicated for use in persons 6 months and older in Can-
ada. In 2006, FluLaval  was licensed in the US where it is
indicated for use in adults aged 18 years and above. The
immunogenicity and safety of FluLaval  was compared to
that of a registered seasonal inﬂuenza vaccine in a phase III
study enrolling 1225 healthy subjects aged 50 years and
above.
15 Non-inferiority of FluLaval  versus the registered
vaccine was demonstrated and both vaccines were well tol-
erated. The comparable safety proﬁle to other marketed
vaccines
15,16 taken together with the long Canadian clinical
experience with this vaccine
17 supports FluLaval  as an
equivalent to other more widely licensed inactivated inﬂu-
enza vaccines.
Fluarix 
Fluarix  is a trivalent-inactivated split-virus inﬂuenza
virus vaccine, containing 15 lg HA from each of the three
recommended strains (H1N1, H3N2 and B). It has been
manufactured in Dresden, Germany, since 1987 and is now
available in more than 100 countries worldwide.
Fluarix  for healthy adult and elderly populations: In the
15 annual European registration studies conducted from
1992 to 2007,
18,19 in which a total of 2112 adult and elderly
subjects were included, a single 0Æ5 ml dose of Fluarix 
was shown to be highly immunogenic, and with only a few
exceptions, meeting or exceeding all three EU⁄CHMP
(Committee for Medicinal Products for Human Use)
immunogenicity criteria for each virus strain (i.e. serocon-
version factor [SCF] >2Æ5 and >2Æ0, seroconversion rate
[SCR] >40% and >30% and seroprotection rate [SPR]
>70% and >60% in subjects aged 18–60 years and
>60 years, respectively) (see Table 1). In adults aged 18–
60 years and elderly subjects aged above 60 years, SPR were
69–100% and consistently exceeded 70% from 1995
onward.
18,19 The vaccine was well tolerated in all age
groups and populations (Table 2). Geometric mean titers
(GMT) of serum antibodies peaked 21 days after vaccina-
tion and remained above the protection level (i.e. % of
vaccinees above an HI titer of 1:40) for all three strains for
up to 12 months in both the adult and the elderly popula-
tion.
18 In a study conducted in elderly institutionalized
patients, GMTs were also shown to be higher 6 months
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21 days post-vaccination from 1992 to 2007*
Groups of volunteers Number of subjects
Seroconversion
factor Seroconversion rate Seroprotection rate
H1N1 H3N2 B H1N1 H3N2 B H1N1 H3N2 B
Adults 18–60 years** 2049 17⁄17 17⁄17 16⁄17 17⁄17 17⁄17 16⁄17 17⁄17 16⁄17 17⁄17
Adults >60 years** 1556 16⁄16 16⁄16 16⁄16 14⁄16 15⁄16 15⁄16 16⁄16 16⁄16 16⁄16
Immunosuppressed cancer adult patients*** 51 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Organ transplant adult patients*** 89 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Diabetes mellitus type 1 adult patients*** 70 Yes Yes Yes Yes Yes Yes Yes Yes Yes
COPD adult patients*** 63 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Source: Hehme et al.,
18 GSK’s clinical trial registry,
19 Campbell et al.
24 and Beran et al.
25
COPD, chronic obstructive pulmonary disease; GMT, geometric mean titer of serum antibodies.
*Immunogenic data for children are discussed in the body text.
**Numbers of studies across studies (17 for healthy adults and 16 for adults >60 years) carried out between 1992 and 2007 for which EU⁄CHMP
immunogenicity criteria for each virus strain were met or exceeded.
***As CHMP does not specify any immunogenicity criteria for patients at high risk of developing severe inﬂuenza or inﬂuenza complications, the
criteria for 16–60 years of age was used to assess results of these populations. Yes: EU⁄CHMP criteria met or exceeded.
Seroconversion factor deﬁned as the fold increase in serum HI GMTs post-vaccination compared to day 0.
Seroconversion rate for hemagglutinin antibody response is deﬁned as the percentage of vaccinees who have either a pre-vaccination titer <1:10
and a post-vaccination titer ‡1:40 or a pre-vaccination titer ‡1:10 and at least a four-fold increase in post-vaccination titer.
Seroprotection rate deﬁned as the percentage of vaccinees with a serum HI titer ‡40 after vaccination that usually is accepted as indicating
protection.
Table 2. Fluarix : reactogenicity data* recorded within 3 days post-vaccination
Groups of volunteers Number of subjects
Local adverse events General adverse events
Redness (%)** Pain (%)*** Fever (%)
– Other (%)
§
Healthy children 0 to <3 years
# 160 (273 doses) 0–33 8–32 13–27 N.S.
Healthy children 3 to <6 years
# 115 (190 doses) 7–28 16–32 11–28 0–20Æ7
Healthy children 6–18 years
# 263 (386 doses) 10–29 40–63 0–5 0–25
Adults 18–60 years 665 2–26 2–20 0–4 0–23
Healthy adults >60 years 610 0–31 2–38 0–2 2–19
Immunosuppressed cancer patients 23 13 9 4 5
Organ transplant adult patients 94 0 3Æ2 0 0–9
Diabetes mellitus type 1 adult patients 70 1 0 1 0
COPD adult patients 70 14 4 0 10
Source: Hehme et al.,
18 GSK’s clinical trial registry
19 and Schmidt-Ott et al.
26
COPD, chronic obstructive pulmonary disease.
*Reactogenicity data were assessed using severity scales which differed before and after 1996. Only data dating from 1996 to 2007 are presented
in this table except for diabetes mellitus type 1 adult patients for which data were collected in 1995. Numbers are minimal and maximal values
obtained across all studies between 1996 and 2007.
**Data presented for redness in adults and in children >12 years are for reactions >20 mm in diameter and for reactions >5 mm in children
<12 years.
***In adults, data for moderate and severe pain are presented. For children data for any pain are presented.
–Fever was deﬁned as a temperature >38Æ0 C in children ‡3 years, adults and the elderly and >38Æ5 C for children <3 years.
§Other includes malaise, fatigue, headache, myalgia and shivering.
#Whereas adults and children >36 months received a single 0.5 ml dose of the vaccine containing 15 lg of HA per strain, children 6–35 months
received a 0Æ25ml dose of the vaccine, followed, for unprimed children, by a second 0Æ25 ml dose administered at least 4 weeks later.
GSK vaccine portfolio against inﬂuenza
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20
These observations suggest that the vaccine will provide
protection for the whole inﬂuenza season in a high
percentage of both adult and elderly persons. Other studies
have shown that the vaccine induces a rapid immune
response; and a signiﬁcant increase in GMTs from baseline
was measured 7 days after vaccination with the highest lev-
els recorded after 21 days.
21,22 This rapid immune response
suggests that vaccination during an epidemic may still be
beneﬁcial for people who are at risk of the disease because
they have not been vaccinated earlier in the season. Since
2005, Fluarix  has been approved by the Food and Drug
Administration (FDA) for use in the US. A multicenter,
randomized, double-blind study carried out in the US to
obtain this licensure further supported the good reactoge-
nicity proﬁle of Fluarix  against a placebo control.
23 The
solicited symptom rates for swelling, arthralgia, fatigue,
headache, chills and fever did not differ between placebo
and vaccinated subjects. Only mild to moderate myalgia
and injection site pain and redness were more common in
vaccine than placebo recipients. Fourfold or greater
increases in serum HI titers were observed in 60%, 62%
and 78% of subjects and post-vaccination titers of ‡1:40
were achieved in 98%, 99% and 99% of subjects against
the H1, H3 and B components of the vaccine, respectively,
exceeding the pre-speciﬁed immunological criteria for
acceptability for all three antigens.
23 The immunogenicity
and safety of Fluarix  was also compared to that of a reg-
istered inﬂuenza vaccine, in a phase III, observer-blind,
randomized study, which included 1845 healthy subjects
aged 18 years and above.
24 Non-inferiority of Fluarix  ver-
sus the other registered inﬂuenza vaccine was demonstrated
and both vaccines were well tolerated.
24 In a recent ran-
domized, double-blind, placebo-controlled study, which
included 7652 subjects aged 18 to 64 years, a statistically
signiﬁcant vaccine efﬁcacy for Fluarix  was demonstrated
(66Æ9% [51Æ9–77Æ4], P <0 Æ001) against culture-conﬁrmed
inﬂuenza A and⁄or B cases for vaccine antigenically
matched strains as well as against culture-conﬁrmed inﬂu-
enza A and⁄or B cases, for any inﬂuenza strain (61Æ6%
[46Æ0–72Æ8], P <0 Æ001).
25
Fluarix  for high-risk adult populations: Speciﬁc popula-
tion subgroups were also studied. Five studies in high-risk
adult populations (cancer, organ transplant, diabetes mell-
itus type 1 and chronic obstructive pulmonary disease
patients) (n = 273) were carried out between 1992 and
2002 to assess the immunogenicity and safety of inﬂuenza
vaccination. Immunogenicity in these groups exceeded the
target criteria set for healthy adults (Table 1).
18,19
Fluarix  for the paediatric population: Nine studies in
children aged 6 months to 18 years (n = 776) were also
conducted between 1992 and 2006 to assess the immunoge-
nicity and safety of inﬂuenza vaccination in this speciﬁc
population.
18,19,26 At least one criterion set by CHMP for
adults aged 18–60 years (CHMP does not specify any
immunogenicity criteria for children) was met in all trials
after vaccination of individuals who had not been previ-
ously vaccinated with one 0Æ25 or 0Æ5 ml dose.
18,19,26 Sev-
eral studies showed a marked beneﬁt of a second dose in
infants and toddlers who had not been previously vacci-
nated, as well as in children 3–6 years of age: after a second
dose, all CHMP criteria (adult thresholds) were usually
met for the three strains contained in the vaccine.
18,19,26 A
second vaccine dose also substantially increased the
immune response in children aged 6–9 years for the
A⁄H1N1 and the B strains, underlining the overall beneﬁt
of a second dose to children <9 years of age.
26 The results
from safety evaluations showed that Fluarix  is well toler-
ated and associated with a good safety proﬁle in children
(Table 2). No serious adverse events (SAEs) considered as
related to vaccination were reported by investigators.
Based on clinical documentation throughout different
seasons, GSK Biologicals has been granted a license for its
thiomersal-free Fluarix  formulation in Europe in early
2008. The immunogenicity of the thiomersal-free formula-
tion of Fluarix  has also been evaluated in children receiv-
ing two doses, and the vaccine was shown to fulﬁll all three
CHMP criteria deﬁned for adults (i.e. SCF >2Æ5, SCR
>40% and SPR >70%) both in children aged 6–35 months
and in children aged 36–71 months and for all three
strains.
19
New generation inﬂuenza vaccine
It is well known in the medical community that there is
a medical need to improve the protective effects of vacci-
nation in the elderly. The efﬁcacy of vaccination tends to
decline with age. Indeed, although vaccine efﬁcacy against
laboratory-conﬁrmed inﬂuenza illness has been shown to
be between 70% and 90% in healthy adults,
27 it decreases
to 50–60% in community-dwelling elderly people over
the age of 65.
28,29 The protective effects of vaccination in
the elderly can be improved using several approaches,
including adjuvantation of vaccines. Candidate seasonal
inﬂuenza vaccines developed by GSK are currently under-
going clinical evaluation with the aim of enhancing
vaccine response in elderly and immunocompromised
subjects.
Pandemic inﬂuenza
Inﬂuenza viruses constantly mutate and reassort. Some-
times, this can result in the appearance of a novel strain of
highly pathogenic inﬂuenza, completely unknown to the
human immune system, and therefore with high mortality
potential. The appearance in 1997 of the H5N1 strain of
the inﬂuenza virus, which was transmitted from birds to
humans and caused high mortality in infected subjects, and
Baras et al.
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means that the WHO Pandemic Alert Phase is now at level
3 on a scale of 1–6 (humans being regularly infected
by birds, i.e. just one level short of human to human
transmission).
30 There are major concerns that either
H5N1 or another highly virulent subtype of the virus could
at any time reassort or mutate and thus acquire the prop-
erty of human to human transmission leading to a world-
wide pandemic. As we can neither predict the evolution of
the H5 HA nor which strain will trigger a pandemic, it will
not be possible to develop a vaccine matching the actual
pandemic strain until 4–6 months after its emergence. This
means that advance stockpiling of vaccine, a potentially
vital aspect of pandemic preparedness,
31 is only useful if
the stockpiled vaccine can elicit broadly cross-protective
immunity against different H5N1 viruses, including newly
emerged strains. Phylogenetic and antigenic analyses of the
HA of H5N1 viruses collected since 1997 indicate that they
have evolved into different sublineages or clades.
32 Analysis
of the HA sequences of H5N1 isolates collected between
August 2006 and March 2007 indicates that the majority
belong to clades 1 and 2.
33 Clade 1 viruses and 5 subclades
of clade 2 have been distinguished, three of which (clades
2Æ1, 2Æ2 and 2Æ3) have so far been largely responsible for the
recorded human cases.
32,33
Because the threat of a global inﬂuenza pandemic is con-
stant and real, many governments as well as the WHO and
the European Centre for Disease Prevention and Control
(ECDC) are making preparations to attempt to minimize the
impact of such a pandemic. The WHO’s Pandemic Prepared-
ness Plan includes vaccine use, as well as other measures such
as implementation of hygiene measures, limiting contact and
stockpiling of antiviral drugs. In order to speed up the avail-
ability of pandemic ﬂu vaccines, new European regulatory
procedures were put in place, allowing manufacturers to sub-
mit ‘mock-up’ dossiers, for vaccines identical in composition
and manufacturing method to the eventual pandemic vac-
cine, but containing, instead of the still unidentiﬁed pan-
demic strain, another strain unknown to the human immune
system. The marketing authorization thus obtained could
then quickly be changed in the event of a pandemic to
include the responsible virus strain. GSK was the ﬁrst com-
pany to submit a ‘mock-up’ dossier for a pandemic-
inactivated whole-virus vaccine with traditional alum
adjuvant
34–36 to EMEA in 2005. This vaccine, Daronrix ,
received approval in March 2007. Although whole-virus
vaccines are usually more immunogenic than split-virus
vaccines,
37 split-virus vaccines are in general less reactogenic.
GSK has developed adjuvant systems associated with a good
safety proﬁle that allow strong and broad immune responses
when combined with split-virus antigens.
38,39 Therefore, a
second-generation split-virus pandemic vaccine adjuvanted
with AS03 (GSK proprietary oil-in-water emulsion-based
adjuvant system) was developed, called Pandemrix , for
which GSK now holds a provisional license.
Pandemic vaccines will not be available early during the
pandemic and consequently will only contribute to decrease
morbidity⁄mortality for the late phase of the epidemic. In
this regard, pre-pandemic vaccination is an essential com-
ponent of the Pandemic Preparedness Plan because it is the
only strategy that can be proactively implemented before or
in the early stages of a pandemic and is thus regarded as
the most effective intervention to prevent or attenuate pan-
demic inﬂuenza.
40 The WHO, ECDC and several countries
have already endorsed the pre-pandemic vaccine
approach.
41,42 The WHO has called for development of
such vaccines that use novel vaccine adjuvants, thus
improving immunogenicity, to allow both antigen sparing
and the induction of broadly cross-protective immunity.
43
In this context, GSK Biologicals has used its proprietary
adjuvant system AS03 to develop an inactivated split-virus
H5N1 vaccine containing 3Æ75 lg HA of the strain A⁄Viet-
nam⁄1194⁄2004 NIBRG-14, which is a recombinant H5N1
from clade 1, engineered by reverse genetics
39,44 and rec-
ommended as a prototype pandemic inﬂuenza vaccine
strain by the CHMP. GSK is currently licensed to market
this pre-pandemic inﬂuenza vaccine, called Prepandrix ,i n
all 27 member states of the EU.
Immunogenicity of Prepandrix 
In order to determine the appropriate dose of antigen
required to induce an adequate immune response, and to
evaluate the effect of the AS03-adjuvant, four antigen doses
of an inactivated split virus A⁄Vietnam⁄1194⁄2004 NIBRG-
14 formulation were studied (3Æ75, 7Æ5, 15 and 30 lg HA)
with or without the AS03-adjuvant. Vaccines were adminis-
tered twice 21 days apart to eight groups of 50 volunteers
each, aged 18–60 years.
39 The adjuvanted formulations
were signiﬁcantly more immunogenic than the non-adju-
vanted formulations at all antigen doses. At the lowest anti-
gen dose (3Æ75 lg HA), immune responses for the
adjuvanted vaccine against the homologous vaccine strain
met or exceeded all immunological US FDA and EU licen-
sure acceptance criteria. Furthermore, when assessed by the
more sensitive neutralization assay (which provides an eval-
uation of the vaccine activity against both the HA and the
NA antigens and consequently, gives a more comprehensive
evaluation of the biological activity of the vaccine), 77Æ1%
of participants receiving 3Æ75 lg HA of the AS03-adjuvant-
ed H5N1 candidate vaccine showed an at least four-fold
increase in neutralizing antibodies against a strain derived
by reverse genetics from a drifted H5N1 isolate (A⁄Indone-
sia⁄5⁄2005, subclade 2Æ1) (Table 3). The breadth of this
cross-clade immune response was further demonstrated by
additional analyses in a subset of these subjects,
45 where a
four-fold increase in neutralizing antibodies against geneti-
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against A⁄Anhui⁄1⁄2005 (subclade 2Æ3) H5N1 viruses was
induced by 3Æ75 lg HA of the AS03-adjuvanted H5N1 vac-
cine in 85% and 75% of subjects, respectively. In contrast,
there was no response induced against these strains in the
groups receiving the non-adjuvanted vaccine formulations
(Table 3). At 6 months post-vaccination, 70% and 60% of
subjects who had received adjuvanted vaccine retained neu-
tralizing antibodies against the recombinant subclade 2Æ2
and 2Æ3 strains, respectively, and 40% of these subjects
retained antibodies against the recombinant subclade 2Æ1.
45
Field trials to test the protective efﬁcacy of a pre-pan-
demic vaccine are obviously impossible prior to the onset
of a pandemic. However, evidence regarding protective efﬁ-
cacy can be generated in an appropriate animal model in
which vaccination is followed by challenge with a live virus.
One such study carried out in ferrets has shown that two
doses of the AS03-adjuvanted split H5N1 vaccine A⁄Viet-
nam⁄1194⁄2004 (clade 1) containing 0Æ6–15 lgH A
resulted in 86% (19⁄22 ferrets) protection from death after
a lethal challenge with the homologous A⁄Viet-
nam⁄1194⁄2004 virus (94% [15⁄16] or 100% [11⁄11] pro-
tection with a dose ‡1Æ7o r5 lg HA, respectively).
46
Another study in ferrets has also shown
47 that two doses
of the same adjuvanted split-virus H5N1 vaccine A⁄Viet-
nam⁄1194⁄2004 vaccine containing 1Æ7–15 lg HA induced
neutralizing antibodies in the majority of ferrets to both
clade 1 (74% (17⁄23) responders), and clade 2 viruses
(61% [14⁄23] responders [deﬁned by neutralizing titers
‡1:28]), and that 96% of vaccinated animals survived lethal
challenge with wild-type virus A⁄Indonesia⁄5⁄2005 (clade
2). Full protection (100%, 17⁄17) was seen in ferrets vacci-
nated with two doses containing ‡3Æ75 lg HA. Moreover,
lung virus loads and viral shedding in the upper respiratory
tract were reduced in vaccinated animals. This study
47
therefore not only demonstrated the cross-clade protection
against lethal H5N1 challenge in ferrets with the AS03-ad-
juvanted H5N1 inﬂuenza vaccine but also suggested that
vaccination could markedly attenuate virus shedding
during an infection, thus reducing the risk of viral
transmission.
The cross-clade immunogenicity of this AS03-adjuvanted
H5N1 inﬂuenza vaccine was further demonstrated in a
phase III lot-to-lot consistency study, in which a larger
cohort of Asian adults (aged 18–60 years) received two
doses, 21 days apart, of the H5N1 A⁄Vietnam⁄1194⁄2004
split virus inﬂuenza vaccine containing 3Æ75 lg HA adju-
vanted or not with the AS03 adjuvant system.
48 Twenty-
one days after second vaccination (day 42), SCR of 96%
and 91Æ4% for neutralizing antibodies against the vaccine
strain and the A⁄Indonesia⁄5⁄05 strain, respectively, were
observed in the group receiving adjuvanted vaccine.
48 In
contrast, SCR in the group receiving non-adjuvanted anti-
gen were 32Æ4% and 5Æ6% against the vaccine strain and
the A⁄Indonesia⁄5⁄05 strain, respectively.
48 Furthermore,
despite the HI assay having a greater speciﬁcity toward the
H-antigen than the neutralizing antibody assay, HI sero-
protective titers against the A⁄Vietnam⁄1194⁄2004 and
A⁄Indonesia⁄05⁄2005 strain were observed at day 42 in
94Æ3% and 50Æ2% of subjects in the adjuvanted group.
48 In
the non-adjuvanted group, only 10Æ3% and 0Æ4% of sub-
jects presented HI seroprotective titers against the A⁄Viet-
nam and A⁄Indonesia strain.
48
Prepandrix , the H5N1 vaccine adjuvanted with AS03,
also induced marked immune responses in the elderly pop-
ulation.
49 In children aged 3–9 years, the vaccine contain-
ing 1Æ9 lgH A( A ⁄Vietnam⁄1194⁄2004) adjuvanted with
AS03 demonstrated marked cross-clade immunogenicity.
50
Safety and reactogenicity proﬁles of Prepandrix 
In the study by Leroux-Roels et al.,
39 the most common
adverse event was injection site pain, reported by 90% of
subjects receiving the adjuvanted 3Æ75 lg HA formulation
within 7 days after vaccination. Pain was reported signiﬁ-
cantly less frequently (38%) in the non-adjuvanted 3Æ75 lg
group (P <0 Æ0001). However, no case of severe pain was
reported. Other injection-site adverse events were reported
by less than 30% of subjects in the adjuvanted 3Æ75 lgH A
formulation group (Table 4). The general adverse events
most frequently reported were fatigue and headache, and
were also more frequent in the adjuvanted vaccine groups
than in the non-adjuvanted vaccine groups. These adverse
events were mild to moderate in intensity and were rarely
considered as being related to vaccination (as indepen-
dently assessed by the investigators). The percentage of
subjects reporting at least one unsolicited symptom was
similar in the adjuvanted and non-adjuvanted groups (55%
versus 56% in the 3Æ75 lg HA formulation group) but
unsolicited symptoms were more often considered to be
related to vaccination in the adjuvanted than in the non-
adjuvanted groups (29% versus 10% in the 3Æ75 lg HA for-
mulation group). However, only a minority of unsolicited
adverse events reported by subjects receiving the different
antigen doses were of severe intensity, and all fully
resolved.
These safety results were conﬁrmed in a larger cohort
study conducted in 1206 adults aged 18–60 years old
receiving two injections, 21 days apart, of H5N1 split-virus
vaccine containing 3Æ75 lg HA, adjuvanted or not.
48 Again,
although the adjuvanted vaccine induced more local and
general adverse events than the non-adjuvanted vaccine, its
safety proﬁle was favorable. No SAEs related to vaccination
were reported in this study.
In a phase III, randomized safety trial, a 15 lg HA dose
of the split-virus H5N1 vaccine adjuvanted with AS03 was
compared with the licensed seasonal inﬂuenza vaccine Flu-
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51 Signiﬁ-
cantly more participants in the AS03-H5N1 vaccine group
reported general or local adverse events (84Æ3% versus
40Æ2% of subjects 18–60 years and 69Æ4% versus 34Æ1% of
subjects >60 years, receiving adjuvanted H5N1 antigen and
control, respectively).
51 Injection-site pain was the most
common symptom in both treatment groups within the
7–day post-vaccination period (after ﬁrst dose: 87Æ6% ver-
sus 64Æ5% of subjects 18–60 years and 57Æ8% versus 27Æ1%
in subjects >60 years receiving adjuvanted recombinant
H5N1 and Fluarix , respectively, and after a second dose:
75Æ5% versus 15Æ7% of subjects 18–60 years and 50Æ4%
versus 6Æ1% in subjects >60 years receiving adjuvanted
recombinant H5N1 and placebo, respectively). No SAEs
were related to vaccination.
51 The safety and reactogenicity
proﬁle of the AS03-H5N1 vaccine was shown to be
clinically acceptable, although it had a four-fold higher
antigenic content than Prepandrix  (15 lg versus 3Æ75 lg
HA, respectively).
51
A safety evaluation of the candidate pre-pandemic H5N1
vaccine containing 1Æ9 lg HA adjuvanted with AS03 was
also carried out in a pediatric population of children aged
3–9 years (n = 138) who were given two doses of either the
AS03-adjuvanted H5N1 split-virus inﬂuenza vaccine con-
taining 1Æ9 lg HA (H5N1⁄AS group) or Fluarix  contain-
ing 15 lg HA of each of the three strains recommended
for seasonal inﬂuenza (control group). The candidate
H5N1 AS03-adjuvanted vaccine did not raise any safety
concerns and the reactogenicity proﬁle was considered to
be clinically acceptable.
52,53
Overall, no safety concern has been raised in any of our
clinical trials using the H5N1 vaccine. The AS03-adjuvant-
ed formulation of the vaccine induced superior immunoge-
nicity and a higher incidence of adverse events, although
the vast majority of these adverse events were mild to mod-
erate in intensity and all were transient in nature.
39,48,49,51–
53 No SAEs related to vaccination with AS03-adjuvanted
H5N1 vaccine were reported.
Conclusion
Vaccination is considered to be the one of the most effec-
tive tools to decrease morbidity as well as mortality caused
by inﬂuenza regardless of whether it is for seasonal or pan-
demic viruses.
Speciﬁcally, vaccination of the population with a stock-
piled pre-pandemic inﬂuenza vaccine, either before or at
the immediate onset of a pandemic (phase 6), may signiﬁ-
cantly reduce the impact of the disease, as shown by math-
ematical models.
54,55 This vaccination strategy characterized
by the induction of broadly reactive sub-type immunity
aims to protect against any potential H5N1 pandemic
strain.
31,54–57 In this regard, GSK has obtained licensure of
a pre-pandemic vaccine, Prepandrix  that meets all CHMP
and FDA adult and elderly licensing criteria.
39,48 This split-
virus H5N1 adjuvanted with AS03, a proprietary oil-in-
water emulsion-based adjuvant system, has demonstrated
broad immunity against mutated H5N1 strains
45 and has
been shown to be effective in preventing mortality and viral
shedding in animal studies.
47
GlaxoSmithKline also contributes to decrease the impact
of seasonal inﬂuenza viruses on public health with
Fluarix  and FluLaval . Both vaccines have consistently
been shown to be immunogenic against strains of H1N1,
H3N2 and B and have a good safety proﬁle.
15–25 Although
the efﬁcacy of current trivalent inactivated vaccines has
been demonstrated, GSK is pursuing additional develop-
ment efforts in order to further decrease mortality⁄morbid-
ity caused by inﬂuenza virus, especially in the elderly.
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Table 4. Prepandemic inﬂuenza vaccines: solicited reactogenicity
data recorded 0–6 days after one or both vaccinations in healthy
adults 18–60 years [%; 95% CI]
Vaccine groups
Inactivated split
A/Vietnam/
1194/2004
NIBRG-14
vaccine
containing 3Æ75
lg H5 antigen
(n = 50)
Inactivated
split A/Vietnam/
1194/2004
NIBRG-14
vaccine
containing 3Æ75
lg H5 antigen
with AS03
adjuvant (n = 51)
Solicited local AEs
Pain 38 [24Æ7–52Æ8] 90 [78Æ6–96Æ7]
Redness 18 [8Æ6–31Æ4] 18 [8Æ4–30Æ9]
Swelling 8 [2Æ2–19Æ2] 20 [9Æ8–33Æ1]
Induration 10 [3Æ3–21Æ8] 28 [15Æ9–41Æ7]
Ecchymosis 8 [2Æ2–19Æ2] 16 [7Æ0–28Æ6]
Solicited general AEs
Arthralgia 10 [3Æ3–21Æ8] 28 [15Æ9–41Æ7]
Fatigue 28 [16Æ2–42Æ5] 45 [31Æ1–59Æ7]
Fever 0 [0Æ0–7Æ1] 4 [0Æ5–13Æ5]
Headache 36 [22Æ9–50Æ8] 53 [38Æ5–67Æ1]
Myalgia 16 [7Æ2–29Æ1] 39 [25Æ8–53Æ9]
Shivering 12 [4Æ5–24Æ3] 20 [9Æ8–33Æ1]
Sweating 10 [3Æ3–21Æ8] 18 [8Æ4–30Æ9]
Source: Leroux-Roels et al.
39
AE, adverse event.
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